Form 4: Boston Scientific SVP, GC and Corp. Secretary Vance R Brown Reports Stock Transactions

Vance R Brown, SVP, GC and Corp. Secretary of Boston Scientific, reports multiple transactions involving common stock and restricted stock units, including acquisitions and disposals, from February 13, 2025, to February 17, 2025.

Summary

• Vance R Brown, a Senior Vice President, General Counsel, and Corporate Secretary at Boston Scientific, filed a Form 4 detailing changes in beneficial ownership.
• The report includes transactions from February 13, 2025, to February 17, 2025.
• These transactions involve common stock and derivative securities, specifically restricted stock units and stock options.
• Brown acquired shares through the vesting of restricted stock units and exercised stock options.
• He also disposed of shares to cover tax obligations.
• Following these transactions, Brown directly owns 50,671 shares of Boston Scientific common stock.
• He also holds 4,475 restricted stock units granted on February 13, 2025, and 11,515 stock options granted on February 13, 2025.
• The restricted stock units vest in equal annual installments, starting one year after the grant date.
• The stock options also vest in equal annual installments, starting one year after the grant date and are exercisable at a price of $106.14.

Sentiment

Score: 6

Explanation: The document is neutral, reporting routine stock transactions by an executive. The granting of stock options and restricted stock units is a positive sign, but the disposal of shares for tax obligations is a normal occurrence.

Positives

• The granting of restricted stock units and stock options to a key executive like Vance R Brown can be seen as a positive sign, aligning his interests with the company's long-term performance.

Negatives

• The disposal of shares to cover tax obligations is a routine transaction and doesn't necessarily indicate a negative outlook on the company.

Risks

• There are no specific risks highlighted in this document, as it primarily reports transactions related to stock ownership.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors to gauge management's sentiment and potential future performance.

Comparison to Industry Standards

• Stock option and restricted stock unit grants are common compensation practices in the medical device industry, used to incentivize and retain key executives.
• Companies like Medtronic and Abbott also utilize similar equity-based compensation plans.
• The vesting schedules and terms of these grants are generally in line with industry standards, typically vesting over a four-year period.

Stakeholder Impact

• The transactions reported in this filing may have a minor impact on shareholders, as they provide insight into the actions of a key executive.
• The granting of equity-based compensation can motivate employees and align their interests with those of the shareholders.

Key Dates